Dupilumab (Dupixent) for Asthma
- 12 March 2019
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 321 (10) , 1000-1001
Abstract
This Medical Letter review summarizes doses and formulations of dupilumab (Dupixent), a subcutaneously injected monoclonal antibody add-on maintenance treatmentKeywords
This publication has 5 references indexed in Scilit:
- Faculty Opinions recommendation of Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.2020
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaNew England Journal of Medicine, 2018
- Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe AsthmaNew England Journal of Medicine, 2018
- Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trialThe Lancet, 2016
- Dupilumab in Persistent Asthma with Elevated Eosinophil LevelsNew England Journal of Medicine, 2013